Literature DB >> 18349544

Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.

Mikako Obika1, Toshiyuki Shinji, Shin-Ichi Fujioka, Ryo Terada, Hiromasa Ryuko, Aye Aye Lwin, Hidenori Shiraha, Norio Koide.   

Abstract

AIMS: To prospectively study whether occult hepatitis B virus (HBV) infection can promote the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related chronic liver disease. In addition, to evaluate the difference among HBV DNA-negative patients and patients with high and low HBV copy numbers.
METHODS: A total of 167 patients with HCV-related chronic liver disease without HBV surface antigen (HBsAg) were studied. HBV DNA in liver tissue was determined using polymerase chain reaction (PCR).
RESULTS: HBV DNA was detected in 9 of 167 patients (5.4%) by single PCR and in 25 patients (15.0%) by nested PCR. HCC developed in 12 of 167 patients (7.2%). Ten of 142 HBV DNA-negative patients (7.0%) and 2 of 9 patients with a high HBV copy number (22.2%) developed HCC, whereas none of 16 patients with a low HBV copy number developed HCC. The incidence rate of HCC in patients with a high HBV copy number was significantly higher than in HBV DNA-negative patients and patients with low HBV copy number.
CONCLUSION: A high amount of HBV DNA in liver tissue of HBsAg-negative patients with HCV-related liver disease might be associated with HCC development. Copyright (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349544     DOI: 10.1159/000121363

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  14 in total

1.  Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Arvind Reddy; Elizabeth May; Murray Ehrinpreis; Milton Mutchnick
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.

Authors:  Anna S Lok; James E Everhart; Adrian M Di Bisceglie; Hae-Young Kim; Munira Hussain; Timothy R Morgan
Journal:  Hepatology       Date:  2011-08       Impact factor: 17.425

Review 3.  Diagnosis of hepatitis B.

Authors:  Jeong Eun Song; Do Young Kim
Journal:  Ann Transl Med       Date:  2016-09

Review 4.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

Review 5.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 6.  Role of hepatitis B virus DNA integration in human hepatocarcinogenesis.

Authors:  Hoang Hai; Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Occult hepatitis B virus and hepatocellular carcinoma.

Authors:  Teresa Pollicino; Carlo Saitta
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma.

Authors:  Ming-Ling Chang; Yu-Jr Lin; Chee-Jen Chang; Charisse Yeh; Tse-Ching Chen; Ta-Sen Yeh; Wei-Chen Lee; Chau-Ting Yeh
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

9.  Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  J Cancer       Date:  2013-07-11       Impact factor: 4.207

Review 10.  The clinical significance of occult HBV infection.

Authors:  Giovanni Squadrito; Rosaria Spinella; Giovanni Raimondo
Journal:  Ann Gastroenterol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.